Literature DB >> 1427364

Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma.

S Y Iftikhar1, P D James, R J Steele, J D Hardcastle, M Atkinson.   

Abstract

In a 15 year prospective study of endoscopic surveillance of columnar lined oesophagus, 102 patients with a mean follow up of 54 (12.5) months and total follow up of 462 years have been evaluated. Of all the sets of biopsies taken, 59 in 21 patients were found to exhibit dysplasia or carcinoma. Four male patients had carcinoma of the oesophagus, indicating a 30 times increased risk of development of adenocarcinoma in columnar lined oesophagus. The length of columnar lined oesophagus in subjects with dysplasia was significantly longer as compared with the whole group (p = 0.01) and when compared with the patients without dysplasia (p = 0.005). None of the patients with dysplasia had a columnar lined oesophagus of less than 8 cm. Length of columnar lined oesophagus therefore seems to be a significant risk factor in the development of dysplasia and subsequent carcinoma and intensive follow up of patients with columnar lined oesophagus greater than 8 cm in length is recommended.

Entities:  

Mesh:

Year:  1992        PMID: 1427364      PMCID: PMC1379476          DOI: 10.1136/gut.33.9.1155

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  22 in total

1.  Observer variation in the diagnosis of dysplasia in Barrett's esophagus.

Authors:  B J Reid; R C Haggitt; C E Rubin; G Roth; C M Surawicz; G Van Belle; K Lewin; W M Weinstein; D A Antonioli; H Goldman
Journal:  Hum Pathol       Date:  1988-02       Impact factor: 3.466

2.  Adenocarcinoma and Barrett's esophagus. An overrated risk?

Authors:  S J Spechler; A H Robbins; H B Rubins; M E Vincent; T Heeren; W G Doos; T Colton; E M Schimmel
Journal:  Gastroenterology       Date:  1984-10       Impact factor: 22.682

3.  Dysplasia in Barrett's esophagus. A clinicopathologic study of six patients.

Authors:  R G Lee
Journal:  Am J Surg Pathol       Date:  1985-12       Impact factor: 6.394

4.  Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications.

Authors:  R H Riddell; H Goldman; D F Ransohoff; H D Appelman; C M Fenoglio; R C Haggitt; C Ahren; P Correa; S R Hamilton; B C Morson
Journal:  Hum Pathol       Date:  1983-11       Impact factor: 3.466

5.  Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus.

Authors:  C S Robertson; J F Mayberry; D A Nicholson; P D James; M Atkinson
Journal:  Br J Surg       Date:  1988-08       Impact factor: 6.939

6.  Barrett's oesophagus: a clinical study of 52 patients.

Authors:  B T Cooper; G O Barbezat
Journal:  Q J Med       Date:  1987-02

7.  Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas.

Authors:  A P Naef; M Savary; L Ozzello
Journal:  J Thorac Cardiovasc Surg       Date:  1975-11       Impact factor: 5.209

8.  The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus.

Authors:  S R Hamilton; R R Smith
Journal:  Am J Clin Pathol       Date:  1987-03       Impact factor: 2.493

9.  Barrett's metaplasia and adenocarcinoma of the esophagus and gastroesophageal junction.

Authors:  J J Thompson; K R Zinsser; H T Enterline
Journal:  Hum Pathol       Date:  1983-01       Impact factor: 3.466

10.  Histological and histochemical changes in the columnar lined (Barrett's) oesophagus.

Authors:  G A Rothery; J E Patterson; C J Stoddard; D W Day
Journal:  Gut       Date:  1986-09       Impact factor: 23.059

View more
  50 in total

1.  ACP. Best Practice No 155. Guidelines for handling oesophageal biopsies and resection specimens and their reporting.

Authors:  N B Ibrahim
Journal:  J Clin Pathol       Date:  2000-02       Impact factor: 3.411

2.  Proton pump inhibitors for Barrett's oesophagus.

Authors:  G Triadafilopoulos
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

3.  Combination of endoscopic argon plasma coagulation and antireflux surgery for treatment of Barrett's esophagus.

Authors:  H Tigges; K H Fuchs; J Maroske; M Fein; S M Freys; J Müller; A Thiede
Journal:  J Gastrointest Surg       Date:  2001 May-Jun       Impact factor: 3.452

4.  Guidelines for the management of oesophageal and gastric cancer.

Authors:  W H Allum; S M Griffin; A Watson; D Colin-Jones
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

5.  Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma.

Authors:  J W van Sandick; J J van Lanschot; B W Kuiken; G N Tytgat; G J Offerhaus; H Obertop
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

Review 6.  Surveillance in Barrett's oesophagus: a personal view.

Authors:  K K Basu; J S de Caestecker
Journal:  Postgrad Med J       Date:  2002-05       Impact factor: 2.401

Review 7.  Barrett's esophagus: Clinical issues.

Authors:  Stuart Jon Spechler
Journal:  Gastrointest Endosc Clin N Am       Date:  2011-01

8.  Gastroesophageal reflux disease: relationship between clinical and histological features. GOSPE. Gruppo Operativo per lo Studio delle Precancerosi dell'Esofago.

Authors:  H Aste; L Bonelli; R Ferraris; M Conio; G Lapertosa
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

9.  Three cases of adenocarcinoma arising in extremely long-segment Barrett's esophagus.

Authors:  Toshiya Fujiwara; Yoshio Naomoto; Tomoki Yamatsuji; Yasuhiro Shirakawa; Hirofumi Noguchi; Toshiyoshi Fujiwara; Nobuya Oohara; Mehmet Gunduz; Hitoshi Nagatsuka; Manabu Nishie; Hirokazu Uetsuka; Shuji Hamazaki; Noriaki Tanaka
Journal:  Dig Dis Sci       Date:  2006-03       Impact factor: 3.199

10.  Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.

Authors:  M Solaymani-Dodaran; R F A Logan; J West; T Card; C Coupland
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.